Drugs Development and Fragile X Syndrome Translational Success Story
Sažetak
-
Reference
Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010; 9(3):203-14.
Collier R. Drug development cost estimates hard to swallow. CMAJ 2009; 180(3):279-80.
Emanuel EJ. The Solution to Drug Prices. New York Times 2015.
Todorović Z, Prostran M, Turza K, editors. Bioethics and Pharmacology: Ethics in Preclinical and Clinical Drug Development. Kerala, India: Transworld Research Network, 2012.
http://www.oecd.org/chemicalsafety
Blake-Anson D, Junyi M, Jia-Qiang, H. Identifying Cardiotoxic Compounds. Genetic Engineering & Biotechnology News. TechNote 2009; 29 (9): 34–35.
Leeson PD, Springthorpe B. "The influence of drug-like concepts on decision-making in medicinal chemistry". Nature Reviews. Drug Discovery 2007; 6 (11):881–90.
Bosch F, Rosich L. The contributions of Paul Ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize. Pharmacology 2008; 82(3):171-9.
Black J. "Drugs from emasculated hormones: the principles of synoptic antagonism. Nobel Lecture 1988."
Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992; 33(11):1569-82.
Rask-Andersen M, Almén MS, Schiöth HB. "Trends in the exploitation of novel drug targets". Nature Reviews. Drug Discovery 2011; 10(8):579–90.
Agis-Torres A, Sölhuber M, Fernandez M, Sanchez-Montero JM. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. Curr Neuropharmacol 2014; 12(1):2-36.
Westmark CJ. The quest for fragile X biomarkers. Mol Cell Pediatr 2014; 1(1):1.
Budimirovic DB, Bukelis I, Cox C, Gray RM, Tierney E, Kaufmann WE. Autism Spectrum Disorder in Fragile X Syndrome: Differential Contribution of Adaptive Socialization and Social Withdrawal. Am J Med Genet 2006; 140A (17):1814-26.
Budimirovic DB, Kaufmann WE. What Can We Learn About Autism from Studying Fragile X Syndrome? Dev Neurosci 2011; 33(5):379-94.
Budimirovic DB, Subramanian M. Neurobiology of Autism and Intellectual Disability: Fragile X Syndrome. In: Johnston MV, editor. Neurobiology of Disease. New York: Oxford Univ Press; 2016. p. 375-384.
KaufmannWE, Capone G, Clarke M, Budimirovic,DB (2008). Autism in Genetic Intellectual Disability: Insights into Idiopathic Autism. In: Zimmerman AW, editor. Autism: Current Theories and Evidence. Totowa, NJ: The Humana Press Inc; 2008. p. 81-108.
Sherman S. (2002). Epidemiology. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: Diagnosis, treatment, and research. Baltimore, MD: Johns Hopkins University Press; 2002. p. 136– 9.
Edbauer D, Neilson JR, et al. Regulation of synaptic structure and function by FMRP- associated microRNAs miR-125b and miR-132. Neuron 2010; 65(3):373– 84.
Bagni C, Tassone F, Neri G, Hagerman, R. Fragile X syndrome: causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 2012; 122(12):4314.
Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004; 27(7):370– 7.
Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008; 60(2):201– 14.
Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000; 10(10): 981– 91.
Darnell JC, Mostovetsky O, Darnell RB. FMRP RNA targets: identification and validation. Genes Brain Behav 2005; 4(6):341– 9.
Dölen G, Bear MF. Fragile X syndrome and autism: from disease model to therapeutic targets. J Neurodev Disord 2009; 1(2):133-40.
Sidorov MS, Auerbach BD, Bear MF. Fragile X mental retardation protein and synaptic plasticity. Molecular brain 2013; 6(1): 1.
Ascano M, Mukherjee N, et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012; 492(7429): 382-6.
D'Antoni S, Spatuzza M, et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev 2014; 46 Pt 2:228-41.
Harony H, Wagner S. The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. Neurosignals 2010; 18(2):82-97.
Iossifov I, Ronemus M, et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012; 74(2):285-299.
Scharf SH, Jaeschke G, Wettstein JG, Lindemann L. Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr Opin Pharmacol 2015; 20:124-34.
Trivedi RR1, Bhattacharyya S. Constitutive internalization and recycling of metabotropic glutamate receptor 5 (mGluR5). Biochem Biophys Res Commun 2012;427(1):185-90.
Hajós M. Portraying inhibition of metabotropic glutamate receptor 5 in fragile X mice. Biol Psychiatry 2014; 75(3):177-8.
Hinton VJ, Brown WT, Wisniewski K, Rudelli RD. Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet 1991; 41(3):289-94.
Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. Cerebral cortex 2000; 10(10): 981-91.
Darnell JC, Fraser CE, et al. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes & development 2005; 19(8): 903-18.
Budimirovic D, Haas-Givler B, et al. Consensus of the Fragile X Clinical and Research Consortium on Clinical Practices Autism Spectrum Disorder In Fragile X Syndrome. National Fragile X Foundation Website Pages 2014; 1-15
Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annual Review of Pathology: Mechanisms of Disease 2012; 7:219-45.
Darnell JC, Van Driesche SJ, et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011; 146(2): 247-61.
Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10(1):31-41.
De Rubeis S, Xin H, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515(7526):209-15.
Castrén ML. Cortical neurogenesis in fragile X syndrome. Front Biosci (Schol Ed) 2016; 8:160-8.
Uutela M, Lindholm J, et al. (2014). Distinctive behavioral and cellular responses to fluoxetine in the mouse model for Fragile X syndrome. Front Neurosci 2014; 8:150.
Sultana R, Perluigi M, Butterfield DA. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal 2006; 8(11-12): 2021-37.
de Diego-Otero Y, Romero-Zerbo Y, et al. α-tocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 2009; 34(4):1011-26.
Lauterborn JC, Rex CS, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007; 27(40): 10685-94.
Erickson CA, Ray B, et al. Impact of acamprosate on plasma amyloid-β precursor protein in youth: A pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. J Psychiatr Res 2014; 59:220-8.
Castrén M, Lampinen KE. BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiology of disease 2002; 11(1):221-9.
Lee EK, Kim HH, et al. hnRNP C promotes APP translation by competing with FMRP for APP mRNA recruitment to P bodies. Nat Struct Mol Biol 2010; 17(6):732-9.
Westmark CJ, Malter JS. FMRP mediates mGluR 5-dependent translation of amyloid precursor protein. PLoS Biol 2007; 5(3):e52.
Hagerman RJ, Berry-Kravis E, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009; 123(1):378-90
Pretto D, Yrigollen CM, et al. Clinical and molecular implications of mosaicism in FMR1 full mutations. Front Genet 2014; 5:318.
Faqi A, editor. A Comprehensive Guide to Toxicology in Preclinical Drug Development. Waltham, Massachusetts: Academic Press; 2012.
Russell WMS, Burch RL. The principles of humane experimental technique. London, UK: Methuen & Co; 1959.
Froestl W, Muhs A, Pfeifer A.. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. J Alzheimers Dis 2012; 32(4):793-887.
Gantois I, Pop AS, et al. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 2013; 239:72-9.
Pop AS, Levenga J, et al. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology 2014; 231(6):1227-35.
Henderson C, Wijetunge L, et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med 2012; 4(152):152ra128.
Curtis LM, Tonascia S. Clinical trials: design, conduct, and analysis. USA: Oxford Univ Press; 1986.
Friedman LM, Furberg CD, DeMets D, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. USA: Springer; 2015.
Budimirovic DB, Phan DQ. Neurobehavioral Features and Targeted Treatments in Fragile X Syndrome: Current insights and Future Directions. Engrams 2015; 37(4):5-19
Budimirovic DB, Phan DQ. Challenges in Translating Therapeutic Frontiers in Clinical Trials: Where Are We Now and What’s Next? Madridge J Neuro Sci 2016; 1(1): e1-e3.
Berry-Kravis E, Budimirovic D, et al. (2016, under review JNDD-D-16-00048). Arbaclofen in Fragile X Syndrome: Results of Phase 3 Trials. J Neurodev Disord. An original invited paper.
Bailey DB, Raspa M, et al. Parent ratings of ability to consent for clinical trials in fragile X syndrome. J Empir Res Hum Res Ethics. 2014; 9(3):18-28.
des Portes V, Kim E, Koumaras B, Ferrer Playan J, Slater L, Zhu L, Kalim J, von Raison F, Apostol G. Mavoglurant in adolescent patients with fragile X syndrome: results of a randomized, double-blind, placebo controlled study. 14th International Fragile X Conference, Orange County, CA, USA, July 16-20, 2014. [poster]
Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B. Translating molecular advances in fragile X syndrome into therapy: a review. J Clin Psychiatry 2014; 75(4):e294-307.
Jacquemont S, Curie A, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011; 3(64):64ra1.
Jacquemont S, Berry-Kravis E, et al. The challenges of clinical trials in fragile X syndrome. Psychopharmacology (Berl) 2014; 231(6):1237-50.
Mattisson C, Bogren M, Horstmann V. Correspondence between clinical diagnoses of depressive and anxiety disorders and diagnostic screening via the Hopkins Symptom Check List-25 in the Lundby Study. Nord J Psychiatry 2013; 67(3):204-13.
Jeste SS, Geschwind DH. Clinical trials for neurodevelopmental disorders: At a therapeutic frontier. Sci Transl Med 2016; 8(321):321fs1.
Budimirovic D, et al. (under review JNDD-D-16-00077). Updates Report on Tools to Measure Outcomes of Clinical Trials in Fragile X Syndrome. J Neurodev Disord 2016a; An invited review.
Erickson C, Budimirovic D, et al. (2016, under submission). Fragile X Targeted Pharmacotherapy: Lessons Learned and Future Directions. J Neurodev Disord. An invited review.
